Achieve Life Sciences Inc. - Common ...





Please Login or Register

Login|Register FREE

Please Login or Register

Login|Register FREE

Stock Price
Open: 3.30
Prev. Close: 3.33
Low/Hi: 3.25 - 3.38
52-Week: 3.25 - 52.68
Equity: 119,593
90-Day Avg: 680,615
Todays Stock Vol: 40.3
20-Day (HV): 166.9
52-Week (HV): 137.0
Div. Yield:
Earnings: 21-Sep (Est.)
P/E Ratio:
Market Cap: 9.2 M
Short Int Pct: 0.0%
Pct Held By Inst.: 5.3%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

About ACHV

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Primary Exchange: NASDAQ
SIC In Vitro & In Vivo Diagnostic Substances
NAICS In-Vitro Diagnostic Substance Manufacturing

ACHV is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ITOT iShares Core S&P Total U.S. Stock Market ETF 14.8 B 1.48461E+10 3,453 3453 0.0% 0 7 K 6711
WMCR Invesco Wilshire Micro-Cap ETF 29.8 M 2.98E+07 978 978 0.01% 0.00013 4 K 3884

Wait, Before You Leave...